Since the blood glucose has been normalized by CSII before GLP-1 analogue add-on, the exenatide induced postprandial glucose lowering effect combined with decreased insulin resistance could cause the elevation of SDPG compared to the placebo. The gene discussed is GCG; the disease is Insulin resistance.